NCT06739291View on ClinicalTrials.gov

A Study of SIGX1094R in Patients With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

December 12, 2024

Primary Completion Date

February 28, 2026

Study Completion Date

June 30, 2026

Conditions
Advanced Solid Tumors
Interventions
DRUG

SIGX1094R

Single drug treatment by SIGX1094R, orally administered once daily.

Trial Locations (1)

Unknown

RECRUITING

Beijing Cancer Hospital, Beijing

Sponsors
All Listed Sponsors
lead

Signet Therapeutics

INDUSTRY

NCT06739291 - A Study of SIGX1094R in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter